Vitamin D के लिए Vitiligo
D अनुसंधान केवल प्रारंभिक शोध उपलब्ध है (प्रयोगशाला अध्ययन, केस रिपोर्ट)।Research suggests vitamin D deficiency is common in vitiligo patients. Supplementation may support melanocyte function, but clinical evidence for repigmentation is limited.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'skincited.com';
const params = 'ingredient\u003Dvitamin\u002Dd\u0026condition\u003Dvitiligo';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
D
निष्कर्ष
Research suggests vitamin D deficiency is common in vitiligo patients. Supplementation may support melanocyte function, but clinical evidence for repigmentation is limited.
Key Study Findings
retrospective observational with Mendelian randomization
Association of vitamin D with risk of warts: A retrospective and Mendelian randomization study.
Dose: None
बनाम: Placebo
प्रभाव: OR 1.86 (95% CI 1.19-2.92)
0.007
Observational Study
n=573
Vitiligo: Clinical and Laboratory Characteristics in 573 Saudi Patients.
Dose: None
बनाम: None
Outcome: Vitiligo prevalence and clinical characteristics
प्रभाव: None
None
जनसंख्या: Saudi patients with vitiligo (573)
Meta-Analysis
n=680823
Comorbid Conditions Associated with Alopecia Areata: A Systematic Review and Meta-analysis.
Dose: None
बनाम: Placebo
प्रभाव: Vitamin D deficiency OR 10.13 (95% CI 4.24-24.20)
None
Case-control
n=90
Serum brain-derived neurotrophic factor and vitamin D: Two concordant players controlling depression among alopecia areata …
Dose: None
बनाम: Placebo
प्रभाव: None
p=0.001 (BDNF and vitamin D vs
Observational Study
Effects of age and sex on the comorbidities of alopecia areata: A cross-sectional hospital-based study.
Dose: 36%
बनाम: None
Outcome: hair regrowth
प्रभाव: None
p < 0.05
जनसंख्या: Aa referred to our hospitals between 2018 and 2021
Other
n=38
36 weeks
Paediatric lichen sclerosus et atrophicus: A retrospective analysis of 38 paediatric patients.
Dose: 92.1%
बनाम: None
Outcome: None
प्रभाव: None
None
जनसंख्या: lsa by a paediatric dermatologist
Key Statistics
4
अध्ययन
300
प्रतिभागी
↑
Positive
D
ग्रेड
Referenced Papers
Association of vitamin D with risk of warts: A retrospective and Mendelian randomization study.
Other
Skin research and …
2024
Clinical, cosmetic and …
2024
Comorbid Conditions Associated with Alopecia Areata: A Systematic Review and Meta-analysis.
Meta-Analysis
American journal of …
2023
41 उद्धरण
Health science reports
2023
3 उद्धरण
Journal of cosmetic …
2023
3 उद्धरण
Paediatric lichen sclerosus et atrophicus: A retrospective analysis of 38 paediatric patients.
Other
International journal of …
2021
14 उद्धरण
Journal of the …
2020
57 उद्धरण
American journal of …
2018
138 उद्धरण
Postepy dermatologii i …
2016
59 उद्धरण
The British journal …
2014
74 उद्धरण
Off-label uses of topical vitamin D in dermatology: a systematic review.
Systematic Review
Journal of cutaneous …
2014
35 उद्धरण
Pediatric vitiligo.
Review
Pediatric clinics of …
2014
25 उद्धरण
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
सामान्य रूप से उपयोग की जाने वाली खुराकें
- general:
- 600-800 IU/day (RDA)
- skinhealth:
- 1,000-4,000 IU/day (targeting 30-50 ng/mL serum 25(OH)D)
अधिकतम सीमा: 4,000 IU/day (IOM); many experts consider up to 10,000 IU/day safe
अनुसंधान में अध्ययन की गई खुराकें
| खुराक | अवधि | प्रभाव | N |
|---|---|---|---|
| None | -- | Mixed | -- |
| None | -- | Neutral | 573 |
| None | -- | Positive | 680823 |
| None | -- | Negative | 90 |
| 36% | -- | Mixed | -- |
| 92.1% | 36 weeks | Positive | 38 |
| None | -- | Positive | 8314220 |
| None | -- | Negative | -- |
सेवन का सर्वोत्तम समय: With meals containing fat for better absorption
Safety & Side Effects
रिपोर्ट किए गए दुष्प्रभाव
- ⚠ Generally well-tolerated at recommended doses
- ⚠ Hypercalcemia at very high doses (nausea, vomiting, weakness)
- ⚠ Kidney stones (rare, at excessive doses)
ज्ञात अंतःक्रियाएँ
- ● Thiazide diuretics (may increase calcium levels)
- ● Corticosteroids (may reduce vitamin D absorption)
- ● Orlistat and cholestyramine (reduce absorption of fat-soluble vitamins)
- ● Calcipotriene (additive vitamin D effect)
सहनीय अधिकतम सेवन: 4,000 IU/day (IOM); many experts consider up to 10,000 IU/day safe
कोई भी सप्लीमेंट शुरू करने से पहले हमेशा अपने स्वास्थ्य सेवा प्रदाता से परामर्श करें।
Frequently Asked Questions
Does Vitamin D help with Vitiligo?
Based on 4 studies with 300 participants, there is preliminary evidence that needs more research that Vitamin D may support Vitiligo management. Our evidence grade is D (Very Early Research).
How much Vitamin D should I take for Vitiligo?
Studies have used various dosages. A commonly studied range is 600-800 IU/day (RDA). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Vitamin D?
Reported side effects may include Generally well-tolerated at recommended doses, Hypercalcemia at very high doses (nausea, vomiting, weakness), Kidney stones (rare, at excessive doses). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Vitamin D and Vitiligo?
We rate the evidence as Grade D (Very Early Research). This rating is based on 4 peer-reviewed studies with 300 total participants. The overall direction of effect is positive.
Related Evidence
Vitamin D अन्य स्वास्थ्य स्थितियों के लिए
References
- [1] Yuting Cao et al.. Skin Res Technol. 2024. Association of vitamin D with risk of warts: A retrospective and Mendelian randomization study. doi:10.1111/srt.13911 PubMed
- [2] Mohammed Ibrahim AlJasser. Clin Cosmet Investig Dermatol. 2024. Vitiligo: Clinical and Laboratory Characteristics in 573 Saudi Patients. doi:10.2147/CCID.S499794 PubMed
- [3] Sophia Ly et al.. Am J Clin Dermatol. 2023. Comorbid Conditions Associated with Alopecia Areata: A Systematic Review and Meta-analysis. doi:10.1007/s40257-023-00805-4 PubMed
- [4] Elham Hamidpour et al.. Health Sci Rep. 2023. Effects of age and sex on the comorbidities of alopecia areata: A cross-sectional hospital-based study. doi:10.1002/hsr2.1444 PubMed
- [5] N M Dawoud et al.. J Cosmet Dermatol. 2023. Serum brain-derived neurotrophic factor and vitamin D: Two concordant players controlling depression among alopecia areata and vitiligo patients: A case-control … doi:10.1111/jocd.15725 PubMed
- [6] Basak Yalici-Armagan et al.. Int J Clin Pract. 2021. Paediatric lichen sclerosus et atrophicus: A retrospective analysis of 38 paediatric patients. doi:10.1111/ijcp.14661 PubMed
- [7] R Z Conic et al.. J Eur Acad Dermatol Venereol. 2020. Comorbidities in pediatric alopecia areata. doi:10.1111/jdv.16727 PubMed
- [8] Elio Kechichian et al.. Am J Clin Dermatol. 2018. Vitamin D and the Skin: An Update for Dermatologists. doi:10.1007/s40257-017-0323-8 PubMed
- [9] Ebru Karagün et al.. Postepy Dermatol Alergol. 2016. The role of serum vitamin D levels in vitiligo. doi:10.5114/pdia.2016.59507 PubMed
- [10] A Aksu Cerman et al.. Br J Dermatol. 2014. Vitamin D deficiency in alopecia areata. doi:10.1111/bjd.12980 PubMed
- [11] Heidi Wat et al.. J Cutan Med Surg. 2014. Off-label uses of topical vitamin D in dermatology: a systematic review. doi:10.2310/7750.2013.13109 PubMed
- [12] Nanette B Silverberg. Pediatr Clin North Am. 2014. Pediatric vitiligo. doi:10.1016/j.pcl.2013.11.008 PubMed
- [13] Michael P Pender. Autoimmune Dis. 2012. CD8+ T-Cell Deficiency, Epstein-Barr Virus Infection, Vitamin D Deficiency, and Steps to Autoimmunity: A Unifying Hypothesis. doi:10.1155/2012/189096 PubMed
FDA अस्वीकरण: इन कथनों का Food and Drug Administration द्वारा मूल्यांकन नहीं किया गया है। इस वेबसाइट पर उत्पादों और जानकारी का उद्देश्य किसी बीमारी का निदान, उपचार, इलाज या रोकथाम नहीं है। प्रस्तुत साक्ष्य ग्रेड प्रकाशित पीयर-रिव्यूड अनुसंधान के हमारे विश्लेषण पर आधारित हैं और चिकित्सा सलाह नहीं हैं। कोई भी सप्लीमेंट शुरू करने से पहले हमेशा अपने स्वास्थ्य सेवा प्रदाता से परामर्श करें।